Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019139714) PYRAZOLOPYRIMIDINE COMPOUNDS AS JAK INHIBITORS
Latest bibliographic data on file with the International BureauSubmit observation

Pub. No.: WO/2019/139714 International Application No.: PCT/US2018/065200
Publication Date: 18.07.2019 International Filing Date: 12.12.2018
IPC:
C07D 487/04 (2006.01) ,A61P 37/00 (2006.01) ,A61P 11/06 (2006.01) ,A61K 31/519 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
487
Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/-C07D477/183
02
in which the condensed system contains two hetero rings
04
Ortho-condensed systems
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37
Drugs for immunological or allergic disorders
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
11
Drugs for disorders of the respiratory system
06
Antiasthmatics
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519
ortho- or peri-condensed with heterocyclic rings
Applicants:
GENENTECH, INC. [US/US]; 1 DNA Way South San Francisco, California 94080, US (US)
F. HOFFMANN-LA ROCHE AG [CH/CH]; Grenzacherstrasse 124 4070 Basel, CH (AllExceptUS)
Inventors:
ZAK, Mark; US
GIBBONS, Paul; US
CHENG, Yun-Xing; CN
GOODACRE, Simon Charles; GB
Agent:
KALE, Tamara A.; US
ACKERMAN, Lily J.; US
AUSENHUS, Scott L.; US
BERENDT, Frank JN; US
BONE, Richard G.A.; US
BUCKWALTER, Brian L.; US
CHANG, Y. Elaine; US
CHI, I. Shannon; US
CLARK, Kevin M.; US
COBURN, Cara M.; US
COLANTONIO, Jessica R.; US
CRISSEY, Todd M.; US
CUI, Steven; US
DAVIS, Jennifer L.; US
DREGER, Ginger; US
DUFFIELD, Jonathan J.; US
GHOSE, Shameek; US
HALL, Robert C.; US
HEIDER, Julie A.; US
HILL, Laurie L.; US
JOHNSTON, Sean A.; US
KAFKA, Mark D.; US
KALINOWSKI, Grant E.; US
LEE, Wendy M.; US
LI, Qianru; US
MCCLELLAN, Kelly B.; US
RICHARDSON, Jessica L.; US
ROPP, Traci H.; US
SCOTT, Derek B.; US
SCHWARTZ, Timothy R.; US
SHERMAN, Daniel E.; US
SHOLTZ, Charles K.; US
TAN, Anna M.; US
TIAN, Zong-Qiang Bill; US
WAIS, Rebecca J.; US
Priority Data:
PCT/CN2018/07256815.01.2018CN
Title (EN) PYRAZOLOPYRIMIDINE COMPOUNDS AS JAK INHIBITORS
(FR) COMPOSÉS PYRAZOLOPYRIMIDINE UTILISÉS EN TANT QU'INHIBITEURS DE JAK
Abstract:
(EN) Compounds and salts thereof that are useful as JAK kinse inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.
(FR) L'invention concerne des composés et des sels de ceux-ci qui sont utiles en tant qu'inhibiteurs de kinase JAK. L'invention concerne également des compositions pharmaceutiques comprenant un tel inhibiteur de JAK et un transporteur, adjuvant ou véhicule pharmaceutiquement acceptable, ainsi que des procédés permettant de traiter ou d'atténuer la gravité d'une maladie ou d'une affection sensible à l'inhibition d'une activité de Janus kinase chez un patient.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)